News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
How to Know If a Cryptocurrency Company Is a Scam: CoinsPaid Media Explains
Coinspaidmedia·2026/05/07 11:21
XRP to Print a Big Bullish Candle Next, but the Real Rally Starts at This Level
CryptoNewsNet·2026/05/07 11:18
The “never sell” Bitcoin treasury trade is seriously starting to crack
CryptoSlate·2026/05/07 11:12
Pourquoi ce projet cross-chain attire alors que le marché temporise
Newsbtc·2026/05/07 11:06
Solana whale bets $8 mln on SOL as price trades near $88 – Is $90 next?
CryptoNewsNet·2026/05/07 11:03
Mapping Filecoin’s road to $1.65 as FIL’s volume spikes 405%
CryptoNewsNet·2026/05/07 11:03
Yellow Card Partners with MasterCard to Streamline Cross-Border Payments
BlockchainReporter·2026/05/07 11:00
Bitwise CEO says four-year crypto cycle is dead as institutional era takes hold
The Block·2026/05/07 11:00
Crypto News From Consensus Miami: Arthur Hayes Latest Take on Bitcoin and Crypto Market
Coinspeaker·2026/05/07 10:54
Altcoins climb as bitcoin and ether retreat from weekly highs
CryptoNewsNet·2026/05/07 10:51
Flash
16:54
LME copper futures closed up by $54, at $13,649 per ton.LME aluminum futures closed down by 32 USD, at 3,364 USD/ton. LME zinc futures closed up by 52 USD, at 3,608 USD/ton.
16:52
Arrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).FCS is a rare and severe genetic disease characterized by extremely high levels of triglycerides in the blood, which can lead to life-threatening pancreatitis. This approval marks a significant advancement for Arrowhead Pharmaceuticals in the field of rare disease treatments, providing a new treatment option for FCS patients in Europe. The company stated that it is committed to bringing this innovative therapy to patients in need as soon as possible.
16:43
Ethereum Foundation Co-Executive Director Hsiao-Wei Wang announces resignationEthereum Foundation Co-Executive Director Hsiao-Wei Wang announced her resignation, and the Ethereum community is discussing the future of the Ethereum Foundation leadership.
Trending news
MoreArrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).
Bitcoin Supply Crunch? OTC Balances Drop by 400,000 BTC Since 2022